AOD-9604: The Anti-Obesity Peptide Fragment Explained

This article is for research and educational purposes only. Not medical advice.

Origins of AOD-9604

AOD-9604 — the "Anti-Obesity Drug" — is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 177–191. It was developed by Metabolic Pharmaceuticals, an Australian biotechnology company, based on research conducted at Monash University in Melbourne during the 1990s.

The compound emerged from a specific research question: human growth hormone produces multiple effects in the body, including fat mobilisation, muscle anabolism, and IGF-1 stimulation. Researchers sought to identify whether the lipolytic (fat-burning) component of hGH activity could be isolated to a specific molecular region — enabling targeted fat loss research without the broader hormonal effects of full hGH administration.

They identified the C-terminal region (residues 177–191) as the primary lipolytic domain.

Mechanism of Action

AOD-9604's primary studied mechanism involves beta-3 adrenergic receptors on adipose tissue. Activation of these receptors promotes:

• Lipolysis — breakdown of stored triglycerides in fat cells into free fatty acids
• Inhibition of lipogenesis — suppression of new fat synthesis from dietary carbohydrate
• Increased energy expenditure — elevated metabolic rate in some animal study designs

Unlike full growth hormone, AOD-9604 does not appear to significantly elevate IGF-1 levels, does not stimulate cell proliferation pathways, and does not cause glucose intolerance at studied doses in animal models. This selective profile was the therapeutic rationale for its development as a standalone compound.

There is also some proposed interaction with beta-3 adrenergic receptors in the context of broader weight loss peptides under investigation, where complementary mechanisms targeting different metabolic pathways are of research interest.

Animal Research Findings

Foundational studies at Monash University used diet-induced obese mouse models and found:

• Dose-dependent reductions in body fat over extended administration periods
• Body weight approaching that of lean control animals at sufficient doses
• Preservation of lean mass relative to fat mass loss
• No effects on linear growth or bone density, consistent with the absence of IGF-1 stimulation

These rodent findings were sufficiently compelling to progress the compound into human clinical trials — an unusual outcome for a research peptide.

A relevant study examining the lipolytic effects of this fragment is available on PubMed: Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000;53(6):274-8.

Human Clinical Trial History

Metabolic Pharmaceuticals advanced AOD-9604 through Phase I and Phase II trials in the early 2000s under TGA and FDA regulatory frameworks — making it one of the few weight loss peptides to have reached human clinical testing:

Phase I: Established a reasonable safety and tolerability profile. No serious adverse events attributed to the compound.

Phase II (METAOD study): Approximately 300 obese adults were randomised to receive oral AOD-9604 at various doses or placebo over 12 weeks. Results showed modest but statistically significant weight reduction compared to placebo at certain doses. The effect size was approximately 1–2 kg beyond placebo — clinically modest.

Phase IIb/III: Trials were halted when results did not demonstrate the degree of efficacy required for regulatory approval as a pharmaceutical anti-obesity drug. The compound did not produce the magnitude of weight loss needed to achieve a viable therapeutic risk-benefit profile in the regulatory context of the early 2000s.

Regulatory Status and GRAS Designation

Following the failure to gain pharmaceutical approval, AOD-9604 was subsequently granted GRAS (Generally Recognised as Safe) status by the US FDA — allowing its use as a food ingredient. It has been incorporated into some functional food and supplement formulations in the US under this classification.

This is an important distinction: GRAS status relates to safety as a food ingredient, not to efficacy as a pharmaceutical. It should not be interpreted as regulatory approval for weight loss claims.

In Australia, the TGA classifies AOD-9604 as a Schedule 4 substance — available only on prescription. Its use in a research context requires appropriate compliance with relevant regulations.

How AOD-9604 Compares to Current GLP-1 Agents

The contrast with contemporary GLP-1 agonists is stark. Semaglutide produces approximately 15% body weight reduction; tirzepatide approximately 21%. AOD-9604's Phase II results showed roughly 1–2 kg beyond placebo. The mechanisms are entirely different — AOD-9604 acts peripherally on adipose tissue; GLP-1 agonists act centrally on appetite and glucose metabolism — but the efficacy comparison explains why AOD-9604 did not succeed commercially while GLP-1 therapy did.

For researchers interested in how modern weight loss peptide research compares mechanistically, HGH Fragment 176-191 (the broader category from which AOD-9604 is derived) provides useful context. A broader comparison of AOD-9604 alongside Tesamorelin and Semaglutide — covering their distinct mechanisms, evidence bases, and Australian regulatory status — is covered in the peptide weight loss stack research overview.

Summary

AOD-9604 is an Australian-developed research peptide with a well-characterised mechanism and an unusually complete clinical development history compared to most research peptides. Animal data demonstrated genuine lipolytic activity. Human clinical data confirmed safety but showed modest efficacy insufficient for pharmaceutical approval. Its scientific interest lies in the principle of mechanism isolation — demonstrating that a specific region of growth hormone drives lipolytic activity — rather than its clinical utility as a standalone anti-obesity agent. It represents a useful case study in the gap between compelling animal data and achievable human clinical outcomes.